Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis
Nuria Fernández-Hidalgo,Benito Almirante,Joan Gavaldà,Mercè Gurguí,Carmen Peña,Arístides de Alarcón,Josefa Ruiz,Isidre Vilacosta,Miguel Montejo,Nuria Vallejo,Francisco López-Medrano,Antonio Plata,Javier E. López,Carmen Hidalgo-Tenorio,J. Gálvez,Carmen Sáez,José Manuel Lomas,Marco Falcone,Javier de la Torre,Xavier Martínez-Lacasa,Albert Pahissa +20 more
Reads0
Chats0
TLDR
AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.Abstract:
(See the Editorial Commentary by Munita et al on pages 1269–72.) Background. The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE). Methods. An observational, nonrandomized, comparative multicenter cohort study was conducted at 17 Spanish and 1 Italian hospitals. Consecutive adult patients diagnosed of EFIE were included. Outcome measurements were death during treatment and at 3 months of follow-up, adverse events requiring treatment withdrawal, treatment failure requiring a change of antimicrobials, and relapse. Results. A larger percentage of AC-treated patients (n = 159) had previous chronic renal failure than AG-treated patients (n= 87) (33% vs 16%, P=.004), and AC patients had a higher incidence of cancer (18% vs 7%, P= .015), transplantation (6% vs 0%, P= .040), and healthcare-acquired infection (59% vs 40%, P= .006). Between AC and AGtreated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P=.81) or at 3-month follow-up (8% vs 7%, P= .72), in treatment failure requiring a change in antimicrobials (1% vs 2%, P= .54), or in relapses (3% vs 4%, P=.67). However, interruption of antibiotic treatment due to adverse events was much more frequent in AG-treated patients than in those receiving AC (25% vs 1%, P< .001), mainly due to new renal failure (≥25% increase in baseline creatinine concentration; 23% vs 0%, P< .001). Conclusions. AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.read more
Citations
More filters
Journal ArticleDOI
Actividad in vitro de ampicilina-ceftriaxona frente a aislamientos de Enterococcus faecalis recuperados de infecciones invasivas
TL;DR: In vitro synergy using the ampicillin-ceftriaxone combination was detected and thus, its efficacy was confirmed in the treatment of severe infections by E. faecalis.
Journal ArticleDOI
Phalloplasty Complicated by Penile Artery Thrombosis, Recurrent Extended-Spectrum Beta-Lactamase (ESBL) Urinary Tract Infection (UTI), Colovesical Fistula, and Enterococcus Faecalis Endocarditis
Journal ArticleDOI
Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
TL;DR: Penicillin plus ceftriaxone is a promising alternative to ampicillin plus CeftriAXone for the treatment of Enterococcus faecalis infective endocarditis and similar synergistic activity is demonstrated against E. faecalon clinical blood isolates, but strains with higher penicillin and ceftiaxone MICs less frequently demonstrated synergy.
Journal ArticleDOI
Adjunctive gentamicin did not improve outcome of enterococcal bacteraemia in neutropenic patients: a propensity scored matched study.
TL;DR: In the study with neutropenic patients, treatment with a cell wall-active antibiotic without adjunctive gentamicin for episodes with enterococcal bloodstream infection was as effective as combination therapy with Gentamicin.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Jennifer S. Li,Daniel J. Sexton,Nathan Mick,Richard E. Nettles,Vance G. Fowler,Thomas J. Ryan,Thomas M. Bashore,G. R. Corey +7 more
TL;DR: Modifications of the Duke criteria for the diagnosis of infective endocarditis are proposed, including that positive Q-fever serology should be changed to a major criterion and the minor criterion "echocardiogram consistent with IE but not meeting major criterion" should be eliminated.
Journal ArticleDOI
Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st Century: The International Collaboration on Endocarditis-Prospective Cohort Study
David R. Murdoch,G. Ralph Corey,Bruno Hoen,José M. Miró,Vance G. Fowler,Arnold S. Bayer,Adolf W. Karchmer,Lars Olaison,Paul A. Pappas,Philippe Moreillon,Stephen T. Chambers,Vivian H. Chu,Vicenç Falcó,David Holland,Philip Jones,John L Klein,Nigel Raymond,Kerry Read,Marie Francoise Tripodi,Riccardo Utili,Andrew Wang,Christopher W. Woods,Christopher H. Cabell +22 more
TL;DR: In the early 21st century, IE is more often an acute disease, characterized by a high rate of S aureus infection, and Mortality remains relatively high.
Journal ArticleDOI
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
TL;DR: The ESC Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means as mentioned in this paper.
Journal ArticleDOI
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Gilbert Habib,Bruno Hoen,Pilar Tornos,Franck Thuny,Bernard Prendergast,Isidre Vilacosta,Philippe Moreillon,Manuel J. Antunes,Ulf Thilén,John Lekakis,Maria Lengyel,Ludwig Müller,Christoph Naber,Petros Nihoyannopoulos,Anton Moritz,José Luis Zamorano,M. O. Evseev +16 more
TL;DR: Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009).
Related Papers (5)
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association
Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st Century: The International Collaboration on Endocarditis-Prospective Cohort Study
David R. Murdoch,G. Ralph Corey,Bruno Hoen,José M. Miró,Vance G. Fowler,Arnold S. Bayer,Adolf W. Karchmer,Lars Olaison,Paul A. Pappas,Philippe Moreillon,Stephen T. Chambers,Vivian H. Chu,Vicenç Falcó,David Holland,Philip Jones,John L Klein,Nigel Raymond,Kerry Read,Marie Francoise Tripodi,Riccardo Utili,Andrew Wang,Christopher W. Woods,Christopher H. Cabell +22 more
Infective Endocarditis Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Larry M. Baddour,Walter R. Wilson,Arnold S. Bayer,Vance G. Fowler,Ann F. Bolger,Matthew E. Levison,Patricia Ferrieri,Michael A. Gerber,Lloyd Y. Tani,Michael H. Gewitz,David C. Tong,James M. Steckelberg,Robert S. Baltimore,Stanford T. Shulman,Jane C. Burns,Donald A. Falace,Jane W. Newburger,Thomas J. Pallasch,Masato Takahashi,Kathryn A. Taubert +19 more